CDK4 and neoplasm: Upon disease progression, we used a targeted systemic approach based on the whole genomic profile of the primary tumor, which showed <i>PTEN</i> loss, which is predictive of a benefit from an mTOR inhibitor, and a <i>CCND1</i> amplification, which predicts sensitivity to CDK4/6 inhibitors.